Comparison of Cefazolin versus Ceftriaxone for Surgical Site Infection Prevention and Predictors of Surgical Site Infection in Gynecologic Surgery Authors: Aisyah Shofiatun Nisa, Gatot Nyarumenteng Adhipurnawan Winarno, Nurvita Trianasari, Artha Falentin Putri Susilo Published: 2026 ABSTRACT AbstractBackgroundSurgical site infection (SSI) is a significant postoperative complication in gynecological surgery, increasing morbidity, mortality, and healthcare costs. This study aimed to compare postoperative surgical site infection (SSI) outcomes between patients receiving cefazolin or ceftriaxone as preoperative antibiotics and to identify clinical predictors of postoperative SSI.MethodsThis retrospective cohort study involved 366 gynecological surgery patients at Dr. Hasan Sadikin General Hospital, Bandung. Medical record data were analyzed using bivariate analysis and multivariable logistic regression. Variables analyzed included age, body mass index (BMI), hemoglobin, leukocyte count, neutrophil-to-lymphocyte ratio (NLR), and type of antibiotic used (cefazolin or ceftriaxone). The primary outcome was postoperative surgical site infection documented during postoperative follow-up.ResultsNo significant difference was found between cefazolin and ceftriaxone in the incidence of surgical site infection (p = 0.097). However, several clinical parameters were significantly associated with SSI. A BMI > 24.89 kg/m2 was associated with an odds ratio (OR) of 4.27 (95% CI: 2.74–6.65). Leukocyte count > 12,580/μL had an OR of 2.31 (95% CI: 1.44–3.69). An NLR > 14.68 showed an OR of 2.53 (95% CI: 1.65–3.89). Lower hemoglobin levels (<11.9 g/dL) were associated with an OR of 2.70 (95% CI: 1.67–4.35), while hematocrit ≤32.5% showed an OR of 2.47 (95% CI: 1.58–3.87). The area under the curve (AUC) value for NLR was 0.641, indicating modest discriminative ability in predicting SSI.DiscussionCefazolin and ceftriaxone were associated with comparable postoperative SSI outcomes in this retrospective cohort. Considering antimicrobial stewardship principles and Indonesian national guidelines, cefazolin may be preferred as the first-line preoperative antibiotic. Higher BMI, leukocytosis, elevated NLR, and anemia were associated with an increased risk of SSI and may help identify patients at greater postoperative risk.ConclusionCefazolin and ceftriaxone showed comparable postoperative SSI outcomes in this retrospective cohort. BMI, hemoglobin level, hematocrit, and NLR were independent predictors of postoperative SSI.Keywords: surgical site infection, cefazolin, ceftriaxone, antibiotics Introduction Surgical site infection (SSI) is defined as an infection occurring at the incision site within 30 days post-surgery, or up to one year if a permanent implant is placed.1 SSI is one of the components of healthcare-associated infections (HAIs) that contributes to increased morbidity, mortality, and healthcare costs.1,2 SSIs account for approximately 20% of all HAIs and may increase the risk of mortality by 2–11 times.3 According to the World Health Organization (WHO), one in ten patients undergoing surgery in low- and middle-income countries develops an SSI.4 In Africa, up to 20% of caesarean deliveries are complicated by SSI.4 In Europe, over 500,000 cases occur annually, with a total financial burden of €19 million.4 In the United States, SSIs account for more than 400,000 additional hospital days each year, with costs exceeding US$10 billion.4 Furthermore, between 39–51% of SSI-causing pathogens are resistant to standard antibiotics.4 The risk of SSI can be reduced through appropriate administration of preoperative antibiotics and standardized aseptic techniques. The interaction between invading bacteria and antibiotics is a key determinant of wound outcomes.5 The administration of preoperative antibiotics is based on the principle that achieving adequate tissue concentrations at the time of incision reinforces innate immune defenses and helps eradicate bacteria introduced during surgery.5 In gynecological surgery, preoperative antibiotics are usually administered within one hour before skin incision, typically during induction of anesthesia.5 According to the American College of Obstetricians and Gynaecologists (ACOG), cephalosporins are recommended as the first-line agents for most surgical procedures, owing to their broad antimicrobial spectrum, low incidence of hypersensitivity reactions, and favourable safety profile. Cefazolin is the most frequently used option due to its relatively long half-life (1.8 hours) and cost-effectiveness.5 Repeat dosing is advised for operations lasting longer than three hours or with blood loss exceeding 1.5 litres.6 Ceftriaxone, a third-generation cephalosporin, provides broader Gram-negative coverage than cefazolin. However, according to the Indonesian National Guideline for Antimicrobial Use, ceftriaxone is classified within the WHO Watch group because of its higher potential to promote antimicrobial resistance.6 Despite these recommendations, ceftriaxone continues to be used for surgical prophylaxis in some clinical settings because of surgeon preference and local prescribing practices. Consequently, comparing postoperative SSI outcomes between patients receiving cefazolin and ceftriaxone as preoperative antibiotics is clinically relevant for evaluating current prescribing practices. In addition to antibiotic prophylaxis, several patient-related factors have been associated with postoperative wound infection. Obesity may impair tissue perfusion and wound healing, anemia reduces tissue oxygenation, while leukocytosis and an elevated neutrophil-to-lymphocyte ratio (NLR) reflect systemic inflammatory responses that may increase susceptibility to postoperative infection. These readily available clinical and hematological parameters have therefore been proposed as potential predictors of adverse postoperative wound outcomes. Because prophylactic antibiotic selection in routine clinical practice is frequently influenced by surgeon preference and patient characteristics, retrospective observational studies are inherently susceptible to confounding. Therefore, identifying independent predictors while comparing antibiotic groups is essential for a more balanced interpretation of the findings. Given current guideline recommendations favoring cefazolin for surgical antibiotic prophylaxis, we anticipated that postoperative SSI rates would be comparable between patients receiving cefazolin and ceftriaxone, while clinical and hematological parameters would independently predict postoperative SSI. This retrospective study aimed to compare postoperative surgical site infection (SSI) rates between patients receiving cefazolin or ceftriaxone as preoperative antibiotics during gynecologic surgery and to identify clinical and hematological factors associated with postoperative SSI. Methods This retrospective cohort study was conducted to compare postoperative surgical site infection (SSI) outcomes between patients receiving cefazolin or ceftriaxone as preoperative antibiotics for gynecological surgery at Dr Hasan Sadikin General Hospital, Bandung. Medical records of eligible patients who underwent surgery between January 2023 and December 2024 were retrospectively reviewed. Data extraction from the hospital medical records was performed between July and December 2025. The study population consisted of patients who underwent gynecological surgery and received either cefazolin or ceftriaxone as preoperative antibiotics between January 2023 and December 2024. According to the institutional protocol, preoperative antibiotics are routinely administered within 60 minutes before skin incision. Information regarding intraoperative redosing was not consistently available in the medical records and therefore was not analyzed. The sample was drawn from medical records of patients who received either cefazolin or ceftriaxone, in accordance with the inclusion and exclusion criteria. A purposive sampling technique was applied to select cases that met the predefined criteria, ensuring that the study sample had the desired characteristics. The inclusion criteria for this study were all patients who received cefazolin or ceftriaxone as preoperative antibiotics for gynaecological surgery at Dr Hasan Sadikin General Hospital, availability of complete medical record data. While the exclusion criteria for this study were patients who received combination antibiotic prophylaxis, patients diagnosed with infection or abscess intraoperatively, patients with documented antibiotic allergy, patients with diabetes mellitus, HIV/AIDS, or other severe infectious diseases, and patients who died during hospitalisation. The primary outcome was postoperative surgical site infection (SSI), defined according to the Centers for Disease Control and Prevention (CDC) criteria as a physician-diagnosed wound infection occurring within 30 days after surgery and documented in the medical records. Patients were classified into either the SSI or non-SSI group accordingly. The independent variables included age, body mass index (BMI), hemoglobin level, hematocrit, leukocyte count, neutrophil-to-lymphocyte ratio (NLR), operative duration, estimated blood loss, type of surgery, and preoperative antibiotic administered (cefazolin or ceftriaxone). Because preoperative antibiotic selection was based on routine clinical practice rather than random allocation, potential confounding was addressed using multivariable logistic regression analysis. Information regarding the type and timing of antibiotic administration was obtained from the medical records. Information regarding intraoperative redosing was not consistently documented and therefore was not analyzed. Sample size was calculated using Sample Size 2.0 software (Hosmer and Lemeshow) for an unmatched categorical analytic study with a 95% confidence level and 95% statistical power. The minimum required sample size was 163 participants per group (326 in total). Data distribution was assessed for normality before statistical analysis. Comparisons of baseline characteristics between groups were performed using the independent t-test or the Mann–Whitney U-test for continuous variables, depending on data distribution, and the Chi-square test or Fisher’s exact test for categorical variables, as appropriate. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff values for continuous predictors. Variables with a p-value <0.25 in the bivariate analysis were considered candidates for multivariable logistic regression. Clinically relevant variables were also considered during model development. Adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, and statistical significance was defined as a two-sided p-value <0.05. Data analysis was performed using IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp., Armonk, NY, USA). The investigators were responsible for maintaining participant confidentiality. All patient data were anonymized before analysis, and access to the dataset was restricted to the research team. The study was approved by the Research Ethics Committee of Dr Hasan Sadikin General Hospital (Protocol No. DP.04.03/D.XIV.6.5/253/2025; approval date: 17 June 2025). Result This study included a total of 366 patients. Table 1 presents the baseline characteristics of the study population. The median age was 40 years (13–69), with a median BMI of 24.5 kg/m2 (16.0–41.85). The mean hemoglobin level was 11.15 g/dL (SD 1.63), the mean leukocyte count was 15,268.7/µL (SD 5,916.7), and the median NLR was 14.35 (0.75–97.64). Table 2 shows that among the 366 patients, 202 received ceftriaxone and 164 received cefazolin as preoperative antibiotics. Significant differences were observed between the two groups. Patients in the ceftriaxone group were significantly older than those in the cefazolin group (p < 0.001). The cefazolin group had a higher mean body weight and height than the ceftriaxone group (p = 0.008 and p = 0.006, respectively), whereas BMI did not differ significantly between the groups (p = 0.071). Estimated blood loss and operative duration were significantly greater in the ceftriaxone group than in the cefazolin group (both p < 0.001). No significant difference in the incidence of SSI was observed between the ceftriaxone and cefazolin groups (p = 0.097). However, the distribution of surgical wound classification differed significantly, with clean procedures predominating in the ceftriaxone group (p < 0.001). Table 1Baseline Characteristics of Study Participants (N = 366)VariableValueAge (years)40 (13–69)Body weight (kg)57 (36–93)Height (cm)153.5 (135–175)BMI (kg/m2)24.5 (16.0–41.85)Hemoglobin (Hb)11.15 (1.63)Hematocrit (Ht)34.3 (21.6–46.9)Leukocyte count (/µL)15,268.7 (5,916.7)Platelet count (/µL)305,500 (28,300–637,000)Neutrophil-to-Lymphocyte Ratio (NLR)14.35 (0.75–97.64)Estimated blood loss (mL)500 (10–6,000)Duration of surgery (minutes)150 (0–960)Type of surgery Clean329 (89.8%) Clean-contaminated16 (4.4%) Contaminated5 (1.4%) Infected16 (4.4%)Note: Data are presented as median (range), except for hemoglobin and leukocyte count, which are presented as mean (SD). Baseline Characteristics of Study Participants (N = 366) Note: Data are presented as median (range), except for hemoglobin and leukocyte count, which are presented as mean (SD). Table 2Baseline Characteristics of Patients by Antibiotic GroupCharacteristicCefazolin (n = 164)Ceftriaxone (n = 202)p-valueAge (years)Mean (SD)37.5 (8.9)43.5 (11.2)<0.001Median (range)37 (17–63)43 (13–69)Body weight (kg)Mean (SD)59.5 (10.9)56.6 (10.9)0.008Median (range)60 (40–93)55 (36–90)Height (cm)Mean (SD)154.7 (5.4)153.1 (6.4)0.006Median (range)154 (136–170)153 (135–175)BMI (kg/m2)Mean (SD)24.9 (4.5)24.2 (4.6)0.071Median (range)24.9 (16.6–41.8)23.8 (16–37.8)Estimated blood loss (mL)Mean (SD)548.5 (644.4)837.4 (883.1)<0.001Median (range)400 (10–5000)500 (10–6000)Duration of surgery (minutes)Mean (SD)140.2 (60.4)186.9 (98.8)<0.001Median (range)120 (30–450)180 (60–960)Postoperative SSI status0.097SSI59 (36%)90 (44.6%)Non-SSI105 (64%)112 (55.4%)Type of surgery<0.001Clean158 (96.3%)171 (84.7%)Clean-contaminated2 (1.2%)14 (6.9%)Infected3 (1.8%)13 (6.4%)Contaminated1 (0.6%)4 (2.0%)Note: Continuous variables were compared using the Mann–Whitney U-test. The Chi-square test was used to compare postoperative SSI status and type of surgery. Baseline Characteristics of Patients by Antibiotic Group Note: Continuous variables were compared using the Mann–Whitney U-test. The Chi-square test was used to compare postoperative SSI status and type of surgery. Table 3 shows that 149 patients developed SSI, whereas 217 patients did not develop SSI. No significant difference in age was observed between the two groups (p = 0.081). Patients with SSI had significantly higher body weight, lower height, and higher body mass index (BMI) than those in the non-SSI group (all p < 0.01). Significant differences were also observed in laboratory parameters. The SSI group had lower hemoglobin and hematocrit levels, as well as higher leukocyte counts and neutrophil-to-lymphocyte ratios (NLR), than the non-SSI group (all p < 0.01). Intraoperative blood loss was significantly greater in patients with SSI (p = 0.003). Table 3Clinical Characteristics of Patients According to Postoperative Surgical Site Infection (SSI) StatusCharacteristicsSSI (n = 149)Non-SSI (n = 217)p value*Age (years)0.081Mean (SD)41.6 (10.4)40.3 (10.9)Median (range)42 (13–69)39 (15–69)Body weight (kg)<0.001Mean (SD)61.7 (11.6)55.3 (9.8)Median (range)61 (36–93)55 (36–82)Height (cm)0.002Mean (SD)152.9 (5.9)154.4 (6.0)Median (range)152 (139–170)155 (135–175)Body mass index (kg/m2)<0.001Mean (SD)26.4 (4.5)23.2 (4.1)Median (range)26.7 (17.1–41.8)22.4 (16–36.0)Hemoglobin (Hb)<0.001**Mean (SD)10.65 (1.60)11.49 (1.57)Median (range)10.8 (6.8–14.7)11.5 (7.7–15)Hematocrit (Ht)<0.001Mean (SD)32.7 (4.4)35.1 (4.5)Median (range)33 (21.6–41.4)35.4 (23.5–46.9)Leukocyte count (/µL)0.005**Mean (SD)16,311 (5,366)14,553 (6,177)Median (range)16,440 (1,880–32,880)14,140 (2,000–56,200)Platelet count (/µL)0.293Mean (SD)317.5 (104.8)304.7 (85.9)Median (range)310 (28.3–637)295 (112–555)Neutrophil-to-Lymphocyte Ratio (NLR)<0.001Mean (SD)18.28 (11.86)13.12 (9.62)Median (range)17.87 (1.72–97.64)11.5 (0.75–48.86)Estimated blood loss (mL)0.003Mean (SD)824.4 (889.4)628.1 (718.5)Median (range)500 (20–6000)500 (10–6000)Duration of surgery (minutes)0.057Mean (SD)178.0 (104.1)156.9 (72.3)Median (range)165 (60–960)140 (0–420)Type of surgery<0.001 Clean125 (83.9%)200 (92.2%) Clean–contaminated9 (6.0%)7 (3.2%) Contaminated5 (3.4%)0 (0.0%) Infected10 (6.7%)10 (4.6%)Antibiotic use0.097Ceftriaxone90 (60.4%)112 (51.6%)Cefazolin59 (39.6%)105 (48.4%)Notes: *Mann–Whitney test; except for type of surgery and antibiotic use, which were analyzed using the Chi-square test. **Independent t-test. Clinical Characteristics of Patients According to Postoperative Surgical Site Infection (SSI) Status Notes: *Mann–Whitney test; except for type of surgery and antibiotic use, which were analyzed using the Chi-square test. **Independent t-test. Table 4 shows that all evaluated clinical cutoff values were significantly associated with postoperative SSI in the univariable analysis. BMI >24.89 kg/m2 demonstrated the strongest association (OR 4.27, 95% CI 2.74–6.65), followed by hemoglobin ≤11.9 g/dL (OR 2.70, 95% CI 1.67–4.35), NLR >14.68 (OR 2.53, 95% CI 1.65–3.89), hematocrit ≤32.5% (OR 2.47, 95% CI 1.58–3.87), leukocyte count >12,580/µL (OR 2.31, 95% CI 1.44–3.69), and estimated blood loss >300 mL (OR 1.89, 95% CI 1.20–2.98). Receiver operating characteristic (ROC) analysis demonstrated that BMI had the highest discriminative ability (AUC 0.701), followed by hematocrit (AUC 0.645), NLR (AUC 0.641), hemoglobin (AUC 0.640), leukocyte count (AUC 0.611), and estimated blood loss (AUC 0.590). These ROC curves are presented in Figure 1. Table 4Association of Clinical Cutoff Values with Postoperative Surgical Site Infection (SSI)VariablePostoperative SSIP-valueOR (95% CI)SensitivitySpecificityAUCSSINon-SSIN=149N=217Cutoff BMI<0.0014.2765.1%69.6%0.701>24.8997(65%)66(30.4%)(2.74–6.65)<24.8952(34.9%)151(69.6%)Cutoff Hemoglobin<0.0012.7079.2%41.5%0.640<=11.9118(79.2%)127(58.5%)(1.67–4.35)>11.931(20.8%)90(41.5%)Cutoff Hematocrit<0.0012.4745.6%74.7%0.645<=32.568(45.6%)55(25.3%)(1.58–3.87)>32.581(54.4%)162(74.7%)Cutoff Leukocyte<0.0012.3177.2%40.6%0.611>12,580115(77.2%)129(59.4%)(1.44–3.69)<12,58034(22.8%)88(40.6%)Cutoff NLR<0.0012.5361.1%61.8%0.641>14.6891(61.1%)83(38.2%)(1.65–3.89)<14.6858(38.9%)134 (61.8%)Estimated blood loss (mL)>300≤300110 (73.8%)39 (26.2%)130 (59.9%)87 (40.1%)0.0061.89(1.20–2.98)73.8%40.1%0.590Note: OR (95% CI) = Odds Ratio and 95% Confidence Interval. Association of Clinical Cutoff Values with Postoperative Surgical Site Infection (SSI) Note: OR (95% CI) = Odds Ratio and 95% Confidence Interval. Receiver operating characteristic (ROC) curve analysis of (A) Haemoglobin, (B) body mass index, (C) leukocyte count, (D) hematocrit, (E) neutrophil-to-lymphocyte ratio, (F) Estimated blood loss in predicting the study outcome. Table 5 presents the multivariable logistic regression analysis identifying factors independently associated with SSI. Higher BMI (>24.89 kg/m2) was independently associated with the highest adjusted odds of SSI (adjusted OR 4.51, 95% CI 2.79–7.27; p < 0.001). Lower hemoglobin (≤11.9 g/dL) (adjusted OR 2.46, 95% CI 1.35–4.48; p = 0.003), hematocrit ≤32.5% (adjusted OR 1.75, 95% CI 1.01–3.04; p = 0.047), and NLR >14.68 (adjusted OR 2.28, 95% CI 1.42–3.64; p = 0.001) were also independently associated with SSI. The final model demonstrated an overall classification accuracy of 70.8% with a Nagelkerke R2 of 26.8%. Table 5Multivariable Logistic Regression Analysis of Factors Associated with Postoperative Surgical Site Infection (SSI)VariableCoef BSE (B)p valueAdjusted OR (95% CI)BMI (>24.89 kg/m2)1.5060.244<0.0014.51 (2.79–7.27)Hemoglobin (≤11.9 g/dL)0.8990.3070.0032.46 (1.35–4.48)Hematocrit (≤32.5%)0.5590.2820.0471.75 (1.01–3.04)NLR (>14.68)0.8240.2400.0012.28 (1.42–3.64)Notes: Model accuracy = 70.8%. Nagelkerke R2 = 26.8%. Adjusted OR (95% CI) = Adjusted Odds Ratio and 95% Confidence Interval. Multivariable Logistic Regression Analysis of Factors Associated with Postoperative Surgical Site Infection (SSI) Notes: Model accuracy = 70.8%. Nagelkerke R2 = 26.8%. Adjusted OR (95% CI) = Adjusted Odds Ratio and 95% Confidence Interval. Discussion Effectiveness of Antibiotics: Cefazolin vs Ceftriaxone This study compared postoperative surgical site infection (SSI) outcomes between patients receiving cefazolin and ceftriaxone as preoperative antibiotics in gynecological surgery. No statistically significant difference in SSI incidence was observed between the cefazolin and ceftriaxone groups (p = 0.097). These findings suggest that, within this retrospective cohort, both antibiotics were associated with similar postoperative SSI outcomes, although definitive conclusions regarding comparative effectiveness cannot be drawn because of the observational study design. Similar findings have been reported in previous studies demonstrating that first-generation cephalosporins, particularly cefazolin, provide comparable protection against postoperative infections to broader-spectrum cephalosporins in gynecological surgery.7 For example, studies evaluating hysterectomy procedures have shown no significant difference in SSI prevention between first-, second-, and third-generation cephalosporins.7 However, one randomized study involving 511 women undergoing hysterectomy reported a higher SSI rate among patients receiving cefazolin 1 g (11.6%) than among those receiving cefotetan 1 g (6.3%).8 Although our findings suggest comparable postoperative SSI outcomes, they should be interpreted cautiously because antibiotic selection was determined by routine clinical practice rather than random allocation. Baseline differences between the cefazolin and ceftriaxone groups, including patient characteristics and operative factors, may have introduced residual confounding despite multivariable adjustment. Notably, the distribution of surgical types differed substantially between the two groups, with clean procedures being more frequent in the ceftriaxone group. This imbalance likely reflects surgeon preference and real-world prescribing practices rather than standardized treatment allocation. Consequently, the observed similarity in SSI outcomes should not be interpreted as definitive evidence of equivalent effectiveness between the two antibiotics. Current recommendations from the American College of Obstetricians and Gynecologists (ACOG) and the Indonesian Ministry of Health continue to recommend antibiotic prophylaxis with cefazolin as the first-line agent because of its established efficacy, narrower antimicrobial spectrum, lower potential for promoting antimicrobial resistance, favorable safety profile, and lower cost.5 Ceftriaxone, in contrast, is classified within the WHO Watch group because unnecessary use of broad-spectrum antibiotics may contribute to antimicrobial resistance.4,6 Therefore, the present findings should not be interpreted as supporting routine substitution of cefazolin with ceftriaxone, but rather as reflecting comparable outcomes observed under routine clinical practice in this retrospective cohort. Risk Factors Associated with Surgical Site Infections This study identified several clinical and laboratory characteristics associated with postoperative SSI. No significant association was observed between age and SSI (p = 0.081). However, patients who developed SSI had significantly higher body weight and BMI than those without SSI. These findings are consistent with previous evidence demonstrating that obesity impairs tissue perfusion, delays wound healing, and increases susceptibility to postoperative infection. A large cohort study involving 387,919 patients reported a progressive increase in SSI risk with increasing BMI, with relative risks reaching 7.8 (95% CI: 6.0–10.2).9 Patients with SSI also had significantly lower hemoglobin and hematocrit levels than those without SSI, supporting previous evidence that preoperative anemia compromises tissue oxygenation and delays wound healing.10 In addition, leukocyte count and neutrophil-to-lymphocyte ratio (NLR) were significantly higher in patients with SSI, suggesting that systemic inflammatory status may contribute to postoperative infection risk.11 Although intraoperative blood loss was significantly greater in patients with SSI, this variable was not retained as an independent predictor in the multivariable analysis. Likewise, operative duration showed a trend toward longer procedures in the SSI group but did not reach statistical significance. Previous studies have demonstrated that prolonged operative duration increases SSI risk, with Cheng et al reporting a 13% increase in risk for every additional 15 minutes of surgery.12 Predictive Value of Clinical and Laboratory Cut-off Parameters Receiver operating characteristic analysis demonstrated that BMI, leukocyte count, hemoglobin level, and NLR had significant discriminatory ability for identifying patients at increased risk of postoperative SSI. Among these variables, BMI showed the highest discriminative performance (AUC = 0.701), whereas NLR demonstrated modest predictive ability. Multivariable logistic regression further demonstrated that BMI >24.89 kg/m2, hemoglobin ≤11.9 g/dL, hematocrit ≤32.5%, and NLR >14.48 were independently associated with postoperative SSI. These findings suggest that routinely available clinical and laboratory parameters may contribute to perioperative risk stratification; however, their discriminative ability was modest and should be interpreted together with clinical judgment rather than as standalone predictive tools. Study Limitations Several limitations should be considered when interpreting these findings. First, the retrospective observational design is inherently susceptible to selection bias, information bias, and residual confounding. Because the selection of preoperative antibiotics was based on routine clinical practice rather than random allocation, baseline differences between the cefazolin and ceftriaxone groups may have influenced the observed outcomes. Second, although SSI was defined according to CDC criteria and identified from physician-documented postoperative wound infections within 30 days after surgery, misclassification cannot be completely excluded because outcome assessment relied on retrospective medical record documentation. Third, this was a single-center study conducted at a tertiary referral hospital, which may limit the generalizability of the findings to other healthcare settings. Finally, despite multivariable analysis, unmeasured confounding variables that were unavailable in the medical records may have influenced the observed associations. Rationalisation of Antibiotic Use Despite these limitations, this study provides contemporary evidence regarding postoperative SSI outcomes among patients receiving cefazolin or ceftriaxone as preoperative antibiotics in routine gynecological practice. The findings also confirm that obesity, anemia, and systemic inflammatory markers are independently associated with postoperative SSI. These readily available clinical parameters may assist perioperative risk stratification, while cefazolin remains the preferred first-line agent for antibiotic prophylaxis according to current national and international guidelines. Conclusion Postoperative SSI outcomes did not differ significantly between patients receiving cefazolin and ceftriaxone as preoperative antibiotics for gynecological surgery. However, because of the non-randomized study design and baseline differences between the treatment groups, these findings should be interpreted with caution. Higher BMI, lower hemoglobin and hematocrit levels, and elevated NLR were independently associated with postoperative SSI and may assist in perioperative risk stratification.